Pharmacodynamic Substances and Mechanisms of Xinglou Chengqi Tang in Treating Post-stroke Complications： A Review
10.13422/j.cnki.syfjx.20250418
- VernacularTitle:星蒌承气汤在治疗脑卒中并发症中的药效物质和作用机制研究进展
- Author:
Yujin ZHANG
1
;
Xiangzhuo LIU
1
;
Zhouyang CHEN
1
;
Zihao SONG
1
;
Xinyi LIU
1
;
Yizhi YAN
1
;
Chaoya LI
2
;
Yingyan FANG
3
;
Shasha YANG
1
;
Xueqin CHENG
1
;
Zhou XIE
1
;
Sijie TAN
1
;
Peng ZENG
1
;
Yue ZHANG
1
Author Information
1. School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China
2. Chenzhou No．1 People's Hospital，Chenzhou 423000， China
3. Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention， Hubei Polytechnic University School of Medicine，Huangshi 435003， China
- Publication Type:Journal Article
- Keywords:
traditional Chinese medicine;
Xinglou Chengqitang;
post-stroke complications;
pharmacodynamic basisy;
mechanism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(1):327-337
- CountryChina
- Language:Chinese
-
Abstract:
Stroke is the leading cause of death and disability among adults in China， and its common complications include digestive system abnormalities， cognitive impairment， depression， stroke-associated pneumonia， and hemiplegia. The combination of traditional Chinese and Western medicine has great potential in treating post-stroke complications. Xinglou Chengqitang （XLCQT） is a representative prescription of alleviating the disease in the upper part by treating the lower part. It has definite therapeutic effect and high safety. Clinically， XLCQT is often used to treat stroke and its complications. However， the quantity and quality of clinical trials of XLCQT in treating post-stroke complications need to be improved. Additionally， since the basic research is weak， the material basis and multi-target mechanism for the efficacy of this prescription are unknown. This article reviews XLCQT in terms of the pharmacodynamic basis， medicinal properties， safety evaluation， and progress in clinical research and mechanisms in treating post-stroke complications. This article summarizes 22 key active ingredients of XLCQT in treating acute stroke complicated with syndrome of phlegm heat and fu-organ excess. Among these key active ingredients， resveratrol， kaempferol， luteolin， chrysoeriol， apigenin， （+）-catechin， and adenosine have good pharmacokinetic properties and high bioavailability. The mechanisms of XLCQT in treating post-stroke complications are complex， including inflammatory response， brain-gut axis， hypothalamic-pituitary-adrenal （HPA） axis， intestinal flora， neurotrophic factors， autophagy， oxidative stress， and free radical damage. This review helps to deeply understand the pharmacodynamic basis and mechanisms of XLCQT in treating post-stroke complications and provides a theoretical basis for the clinical application of XLCQT against post-stroke complications and the development of drugs.
